[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects",
    "summary": "BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely approval of its acquired...",
    "url": "https://finnhub.io/api/news?id=4b1bec9d6fada3588c3c9faeaeca14408966dc6561c67f87f5d5452f2513014e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734703200,
      "headline": "Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects",
      "id": 132077540,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158301126/image_2158301126.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely approval of its acquired...",
      "url": "https://finnhub.io/api/news?id=4b1bec9d6fada3588c3c9faeaeca14408966dc6561c67f87f5d5452f2513014e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued",
    "summary": "Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a \"Buy\" with strong growth prospects and low valuation.",
    "url": "https://finnhub.io/api/news?id=1da6fd5b0033e0e5251f340fc9be9ed1533bcbd0e0b1009e0098bcae46f1b6ce",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734681600,
      "headline": "Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued",
      "id": 132072359,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160008492/image_2160008492.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a \"Buy\" with strong growth prospects and low valuation.",
      "url": "https://finnhub.io/api/news?id=1da6fd5b0033e0e5251f340fc9be9ed1533bcbd0e0b1009e0098bcae46f1b6ce"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Bristol-Myers Squibb Company (BMY): ‘This Stock Has Been Hot Since The Summer’",
    "summary": "We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently reflected on how investors often overlook obvious […]",
    "url": "https://finnhub.io/api/news?id=9c9893befdacf8bfcd42d6ab6308eeaed6754b035f37d25db3a09c995de463bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734664274,
      "headline": "Jim Cramer on Bristol-Myers Squibb Company (BMY): ‘This Stock Has Been Hot Since The Summer’",
      "id": 132068482,
      "image": "https://s.yimg.com/ny/api/res/1.2/ZsrqNB_sdV78LPtS9DZ12A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently reflected on how investors often overlook obvious […]",
      "url": "https://finnhub.io/api/news?id=9c9893befdacf8bfcd42d6ab6308eeaed6754b035f37d25db3a09c995de463bd"
    }
  }
]